Hodgkin lymphoma (HL) is a rare human B-cell lymphoid malignancy representing 11.4 % of all lymphomas in the United States (Jemal et al. 2009) and with an incidence rate of 2.2 per 100,000 in the more developed countries. (Jemal et al. 2011). The treatment of patients with relapsed and refractory HL, especially those who have disease relapse after autologous stem cell transplantation, remains challenging. However current therapy is expected to cure more than 80 % of these patients.
|Title of host publication||Hematologic Cancers|
|Subtitle of host publication||From Molecular Pathobiology to Targeted Therapeutics|
|Number of pages||22|
|Publication status||Published - Jan 1 2012|
ASJC Scopus subject areas